Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | EP300 | Q09472 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.41 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.38 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7237232 | 0.80 | GRM5 (0.58) | HTTALDH1A1MAPTSMN1; SMN2RAB9A | |
| SCHEMBL12422701 | 0.78 | HTT (0.59) | HTTALDH1A1MAPTSMN1; SMN2RAB9A | |
| SCHEMBL15352616 | 0.78 | ALDH1A1 (0.47) | HTTALDH1A1MAPTSMN1; SMN2LMNA | |
| SCHEMBL15824279 | 0.78 | ALDH1A1 (0.43) | ALDH1A1MAPTSMN1; SMN2LMNACYP2A6 | |
| SCHEMBL2584832 | 0.78 | ALDH1A1 (0.43) | ALDH1A1MAPTSMN1; SMN2LMNAL3MBTL1 | |
| SCHEMBL23176209 | 0.77 | NOTUM (0.45) | ALDH1A1MAPTSMN1; SMN2LMNACYP2A6 | |
| SCHEMBL17356163 | 0.77 | ALDH1A1 (0.41) | ALDH1A1MAPTSMN1; SMN2LMNACYP2A6 | |
| SCHEMBL18865695 | 0.77 | MAPKAPK2 (0.47) | ALDH1A1MAPTSMN1; SMN2LMNACYP2A6 | |
| SCHEMBL5149995 | 0.77 | ALDH1A1 (0.44) | HTTALDH1A1MAPTSMN1; SMN2LMNA | |
| SCHEMBL28734542 | 0.77 | ALDH1A1 (0.48) | HTTALDH1A1MAPTSMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024117179-A1 | KIT INHIBITORS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | ALIVEXIS, INC. (JP) | 2024-06-06 | — | — | WO | disclosed |
| WO-2024117179-A1 | KIT INHIBITORS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | ALIVEXIS, INC. (JP) | 2024-06-06 | — | — | WO | disclosed |
| EP-2934538-B1 | FACTOR IXA INHIBITORS | MERCK SHARP & DOHME (US) | 2021-03-31 | — | — | EP | disclosed |
| EP-2934536-B1 | FACTOR IXa INHIBITORS | MERCK SHARP & DOHME (US) | 2017-09-27 | — | — | EP | disclosed |
| US-9708308-B2 | Factor IXa inhibitors | MERCK SHARP DOHME CORP. (US) | 2017-07-18 | — | — | US | disclosed |
| US-9695198-B2 | Factor IXa inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-07-04 | — | — | US | disclosed |
| US-9271501-B2 | Use of strobilurin type compounds for combating phytopathogenic fungi resistant to QO inhibitors | BASF SE (DE) | 2016-03-01 | — | — | US | disclosed |
| US-20150368269-A1 | Factor IXa Inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-12-24 | — | — | US | disclosed |
| US-20150322056-A1 | Factor IXa Inhibitors | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2015-11-12 | — | — | US | disclosed |
| US-20140323305-A1 | Use of Strobilurin Type Compounds for Combating Phytopathogenic Fungi Resistant to QO Inhibitors | BASF SE (DE) | 2014-10-30 | — | — | US | disclosed |
| WO-2014120346-A1 | FACTOR IXA INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150322056-A1 | Factor IXa Inhibitors | F9, F12, F8 | HTT 1935/4885ALDH1A1 3931/4885MAPT 4751/4885 |
| US-20140323305-A1 | Use of Strobilurin Type Compounds for Combating Phytopathogenic Fungi Resistant to QO Inhibitors | SQOR, COX5B, UQCRB | HTT 2375/4885ALDH1A1 2278/4885MAPT 2644/4885 |
| US-20150368269-A1 | Factor IXa Inhibitors | F9, TFPI, F13B | HTT 2667/4885ALDH1A1 1321/4885MAPT 4555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.